Telomeres — repetitive DNA sequences (TTAGGG) at chromosome ends, protected by shelterin protein complexes — guard chromosomes from being misidentified as DNA breaks. Elizabeth Blackburn and Carol Greider’s discovery of telomerase in 1984 (Nobel Prize 2009) opened telomere biology as a central field in aging research.
## The Shortening Mechanism
Every DNA replication leaves chromosome ends slightly shorter due to the “end-replication problem” — roughly 50–200 base pairs per division. In somatic cells lacking telomerase activity, this shortening is irreversible. After approximately 40–60 divisions, critically short telomeres trigger DNA damage signaling, driving cells into replicative senescence or apoptosis — the “Hayflick limit.”
Telomerase (TERT catalytic subunit + TERC RNA template) extends telomeres and is highly expressed in stem cells, germ cells, and most cancer cells.
## Telomere Length and Health
Epidemiological studies associate shorter leukocyte telomere length (LTL) with higher risk of cardiovascular disease (20–40% increase), type 2 diabetes, certain cancers, and cognitive decline — and with higher all-cause mortality, independently of other risk factors.
The relationship is complex: telomere length is highly heritable (70–80% genetic); very long telomeres may increase risk of some B-cell lymphomas; Mendelian randomization studies support a causal protective effect of longer telomeres on coronary heart disease.
Modifiable factors accelerating shortening: oxidative stress, chronic inflammation, cortisol (psychological stress), smoking, obesity, and physical inactivity. Mediterranean diet, aerobic exercise, and good sleep quality are associated with slower attrition.
## Telomerase Activation: The Double-Edged Strategy
Activating telomerase to extend telomeres is attractive but faces a fundamental problem: telomerase is reactivated in approximately 90% of human cancers, enabling unlimited replication. Systemic telomerase activation carries real cancer risk.
TA-65, extracted from astragalus root, is commercially sold as a telomerase activator; evidence for its benefits is limited and long-term safety data are absent. Gene therapy approaches to local telomerase activation are early-stage. The more widely accepted near-term strategy is removing cells that have entered senescence due to telomere shortening — see [Senolytics](https://sunqi.org/senolytics-anti-aging-en/) and the [Nature Reviews telomere paper](https://www.nature.com/articles/s41576-019-0183-0).
—
